Valuation : Seres Therapeutics, Inc.

Market Cap 5.08Cr 4.37Cr 4.11Cr 3.75Cr 7.04Cr 483.37Cr 7.09Cr 49Cr 19Cr 245.2Cr 19Cr 19Cr 811.52Cr P/E 2026 *
-1.45x
P/E 2027 * -1.03x
Enterprise Value 5.08Cr 4.37Cr 4.11Cr 3.75Cr 7.04Cr 483.37Cr 7.09Cr 49Cr 19Cr 245.2Cr 19Cr 19Cr 811.52Cr EV / Sales 2026 *
3.68x
EV / Sales 2027 * 186x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Seres Therapeutics, Inc.

1 day-3.91%
1 week+5.36%
Current month+1.66%
1 month+1.66%
3 months-35.73%
6 months-44.20%
Current year-67.00%
1 week 4.67
Extreme 4.67
5.15
1 month 4.32
Extreme 4.315
5.65
Current year 4.32
Extreme 4.315
16.42
1 year 4.32
Extreme 4.315
29.98
3 years 4.32
Extreme 4.315
73.4
5 years 4.32
Extreme 4.315
233.8
10 years 4.32
Extreme 4.315
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-3.91%+5.36%-74.85%-92.88% 5.08Cr
-1.66%-4.96%+49.84%+88.43% 6.95TCr
-2.19%+1.32%+44.54%+88.38% 6.5TCr
-3.57%-4.24%+47.11%+5.60% 2.65TCr
+2.77%-1.74%-16.16%+456.51% 2.59TCr
-0.46%-9.94%+0.98%-15.98% 2.56TCr
-9.71%-0.36%+245.87%+377.68% 2.02TCr
-1.58%+0.47%+29.35%-19.62% 2TCr
-3.36%-7.58%+9.47%+535.81% 1.57TCr
+0.35%+0.16%+46.96%+144.04% 1.35TCr
Average -2.33%-2.13%+38.31%+156.80% 2.82TCr
Weighted average by Cap. -2.02%-3.50%+48.06%+145.53%

Financials

2026 *2027 *
Net sales 1.38Cr 1.19Cr 1.12Cr 1.02Cr 1.91Cr 131.28Cr 1.93Cr 13Cr 5.14Cr 67Cr 5.18Cr 5.07Cr 220.41Cr 3L 2L 2L 2L 4L 2.6Cr 4L 26.18L 10.18L 1.32Cr 10.27L 10.05L 4.37Cr
Net income -3.75Cr -3.23Cr -3.03Cr -2.77Cr -5.19Cr -356.71Cr -5.23Cr -36Cr -14Cr -180.95Cr -14Cr -14Cr -598.87Cr -7.9Cr -6.8Cr -6.38Cr -5.83Cr -11Cr -751.27Cr -11Cr -76Cr -29Cr -381.1Cr -30Cr -29Cr -1.26TCr
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
31/26/31 $4.945 -3.23% 43,825
28/26/28 $5.110 +3.23% 32,490
27/26/27 $4.950 +3.99% 22,869
26/26/26 $4.760 -4.80% 58,204
25/26/25 $5.000 +7.30% 1,02,958
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.110USD
Average target price
17.00USD
Spread / Average Target
+232.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock